Kronos Bio Inc
NASDAQ:KRON

Watchlist Manager
Kronos Bio Inc Logo
Kronos Bio Inc
NASDAQ:KRON
Watchlist
Price: 0.959 USD 0.11%
Market Cap: 57.9m USD
Have any thoughts about
Kronos Bio Inc?
Write Note

Kronos Bio Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kronos Bio Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Kronos Bio Inc
NASDAQ:KRON
Cash from Financing Activities
$567k
CAGR 3-Years
-89%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kronos Bio Inc
Glance View

Market Cap
57.9m USD
Industry
Biotechnology

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. The company is headquartered in San Mateo, California and currently employs 96 full-time employees. The company went IPO on 2020-10-09. The firm is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).

KRON Intrinsic Value
1.029 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Kronos Bio Inc's Cash from Financing Activities?
Cash from Financing Activities
567k USD

Based on the financial report for Dec 31, 2023, Kronos Bio Inc's Cash from Financing Activities amounts to 567k USD.

What is Kronos Bio Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-49%

Over the last year, the Cash from Financing Activities growth was -33%. The average annual Cash from Financing Activities growth rates for Kronos Bio Inc have been -89% over the past three years , -49% over the past five years .

Back to Top